Based on these results, we suggest that drugs targeting PARP1, mitochondrial respiration, and ATP synthase may hold potential as chemotherapeutic agents when combined with DNA damage-inducing drugs in cardiovascular diseases, Alzheimer’s disease, and cancer. Here, PARP1 is linked to cardiovascular disorder.